PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3117536-6	1987	Enzyme production in the aztreonam-resistant variants was identical to that in the wild-type strains with a single exception, where the entire derepression of beta-lactamase production in one of the variants took place.	Aztreonam	25-34	Beta lactamase	Pseudomonas aeruginosa	159-173	
1590704-5	1992	Aztreonam therapy lead to opposite results because the beta-lactamase activity decreased and aztreonam was able to mask beta-lactamase activity by acting as an inhibitor.	Aztreonam	0-9	Beta lactamase	Pseudomonas aeruginosa	55-69	
1590704-5	1992	Aztreonam therapy lead to opposite results because the beta-lactamase activity decreased and aztreonam was able to mask beta-lactamase activity by acting as an inhibitor.	Aztreonam	0-9	Beta lactamase	Pseudomonas aeruginosa	120-134	
1590704-5	1992	Aztreonam therapy lead to opposite results because the beta-lactamase activity decreased and aztreonam was able to mask beta-lactamase activity by acting as an inhibitor.	Aztreonam	93-102	Beta lactamase	Pseudomonas aeruginosa	120-134	
3104483-2	1987	For E. cloacae, pre-incubation with ceftriaxone, cefoxitin, cefamandole, cefoperazone, or imipenem produced significantly larger amounts of beta-lactamase than did pre-incubation with moxalactam, clavulanate, ceftazidime, or aztreonam.	Aztreonam	225-234	Beta lactamase	Pseudomonas aeruginosa	140-154	
29046407-0	2018	An Improved Extended-Spectrum-beta-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate.	Aztreonam	70-79	Beta lactamase	Pseudomonas aeruginosa	30-44	
19664245-0	2009	In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.	Aztreonam	34-43	Beta lactamase	Pseudomonas aeruginosa	132-146	
19664245-0	2009	In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.	Aztreonam	85-94	Beta lactamase	Pseudomonas aeruginosa	132-146	
19664245-6	2009	RESULTS: Bacteriostatic effects after 6 hours of drug exposure were observed in 12 strains (52.2%) of 23 strains of metallo-beta-lactamase-producing P. aeruginosa with 48 mg/l aztreonam, in 19 strains (82.6%) with the 3-drug combination of 16 mg/l aztreonam, 16 mg/l ceftazidime, and 4 mg/l amikacin, and in 23 strains (100%) with 2 mg/l colistin.	Aztreonam	176-185	Beta lactamase	Pseudomonas aeruginosa	124-138	
19664245-8	2009	CONCLUSION: Evaluation of in vitro antimicrobial effects on metallo-beta-lactamase-producing P. aeruginosa revealed relatively good effects of the 3-drug combination of aztreonam, ceftazidime and amikacin and marked effects of colistin.	Aztreonam	169-178	Beta lactamase	Pseudomonas aeruginosa	68-82	
18644957-3	2008	The bla(VIM-13)-producing isolate showed resistance to all beta-lactams (except aztreonam), gentamicin, tobramycin, and ciprofloxacin.	Aztreonam	80-89	Beta lactamase	Pseudomonas aeruginosa	4-7